Tysabri (natalizumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Tysabri (natalizumab) market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to Tysabri's efficacy in treating multiple sclerosis, its ability to target specific immune cells, its approval for multiple autoimmune disorders, robust clinical trial data, rising demand for effective disease-modifying therapies, and increasing patient awareness of available treatment options.

Growth during the forecast period will be driven by the increasing prevalence of autoimmune disorders, rising demand for effective treatments for multiple sclerosis and Crohn’s disease, advancements in biosimilars, expanding patient access in underserved regions, and ongoing clinical research supporting its use in other autoimmune conditions. Key trends include the rising adoption of biosimilars, expanding therapeutic applications beyond multiple sclerosis, a stronger focus on personalized medicine, growing global distribution partnerships, enhanced patient access through affordability initiatives, and continued advancements in immune-modulating therapies.

The growth of the tysabri (natalizumab) market is being significantly influenced by the rise in the prevalence of autoimmune disorders. Autoimmune conditions, such as multiple sclerosis and Crohn's disease, occur when the immune system attacks the body’s own tissues, causing inflammation and long-term damage. This increase in autoimmune diseases is linked to genetic factors, environmental influences, and improved awareness and diagnosis, leading to more cases being identified. In March 2024, the National Health Council reported that autoimmune diseases affected approximately 50 million Americans, with the number of cases rising by 3-12% annually. Globally, multiple sclerosis cases grew by 30% in 2022 compared to the previous decade. As a result, Tysabri, which targets specific immune cells to prevent inflammation, is becoming an essential treatment for these conditions, driving market growth.

The rising trend of personalized medicine is propelling the tysabri market. Personalized medicine tailors treatments based on a patient’s genetic makeup, environment, and lifestyle, improving efficacy while minimizing side effects. Tysabri is an example of such treatment, particularly for relapsing forms of multiple sclerosis. It targets specific disease activities and risk profiles, ensuring more precise therapeutic outcomes. The FDA's approval of 16 novel personalized therapies in 2023 highlights the growing demand for targeted treatments, further driving the adoption of Tysabri and similar therapies.

A key trend in the tysabri (natalizumab) market is the growing focus on biosimilars, which offer cost-effective alternatives to branded drugs like Tysabri. In January 2024, Sandoz launched Tyruko (natalizumab), the first biosimilar to Tysabri for the treatment of highly active relapsing-remitting multiple sclerosis (RRMS). This development not only strengthens the biosimilar portfolio but also enhances patient access to effective and affordable treatments, particularly in underserved regions. The increasing availability of biosimilars is expected to expand the market for Tysabri, improving overall disease management and patient outcomes.

Major players operating in the tysabri (natalizumab) market are Biogen Idec Inc., Sandoz International GmbH, and Polpharma Biologics.

North America was the largest region in the tysabri (natalizumab) market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in tysabri (natalizumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the tysabri (natalizumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tysabri (natalizumab) is a monoclonal antibody used to treat relapsing multiple sclerosis (MS) and Crohn's disease by reducing inflammation and nerve damage. It helps decrease the frequency of relapses and slows the progression of physical disability in adults with relapsing forms of MS, including relapsing-remitting MS (RRMS) and active secondary progressive MS (SPMS).

The primary indications for tysabri (natalizumab) are multiple sclerosis and Crohn's disease. Multiple sclerosis is a condition that causes the breakdown of the protective covering of nerves. Tysabri is used in various patient settings, including inpatient and outpatient, and is distributed through multiple channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

The tysabri (natalizumab) market research report is one of a series of new reports that provides tysabri (natalizumab) market statistics, including tysabri (natalizumab) industry global market size, regional shares, competitors with a tysabri (natalizumab) market share, detailed tysabri(natalizumab) market segments, market trends, and opportunities, and any further data you may need to thrive in the tysabri(natalizumab) industry. This tysabri(natalizumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tysabri market consists of sales of monoclonal antibody therapies, infusion treatments, and immunomodulatory solutions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.